Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications
Frontiers in Pharmacology · 31.07.2026 · 17
DOI: 10.3389/fphar.2026.1848964 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.07.2026. Verfasst von Tingting Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, Health System Independent Innovation Science Foundation of Shanghai Putuo District.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Heart failure (HF), the terminal stage of most cardiovascular diseases, remains a major global health burden with limited therapeutic options that do not fully achieve myocardial repair or functional recovery. Extracellular vesicles (EVs), nanoscale membrane-bound particles released by cells, have been increasingly recognized as important mediators in the pathophysiology of HF and as potential therapeutic targets. As intercellular messengers carrying bioactive molecules, including proteins, lipids, and non-coding RNAs, EVs regulate gene expression and functional states in recipient cells. This review summarizes current evidence on the roles of EVs in key pathological processes of HF, including inflammation, mitochondrial dysfunction, myocardial hypertrophy, fibrosis, apoptosis, and angiogenesis. We also discuss their potential as circulating biomarkers for the diagnosis and prognosis of HF. In addition, we describe emerging therapeutic strategies, including stem cell-derived EVs and engineered EVs as delivery platforms for therapeutic molecules. Furthermore, we discuss the pharmacological implications of EVs in current heart failure treatment paradigms, highlighting their potential role in bridging mechanistic insights with clinical therapeutic strategies. Collectively, these findings highlight the relevance of EVs in HF research and suggest directions for future investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
- Neocellmed Co., Ltd., Shanghai, China.
Förderung
- Natural Science Foundation of Shanghai Municipality
- Health System Independent Innovation Science Foundation of Shanghai Putuo District
Zitieren
APA
Li, T., Yang, J., Ding, X., Qi, Z., & Liu, Z. (2026). Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1848964
Vancouver
Li T, Yang J, Ding X, Qi Z, Liu Z. Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1848964
BibTeX
@article{Li2026,
author = {Li, Tingting and Yang, Jin and Ding, Xinyue and Qi, Zhen and Liu, Zongjun},
title = {Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1848964}
}
EUVIMED